Ligand Pharmaceuticals Incorporated $LGND Shares Bought by Quantinno Capital Management LP

Quantinno Capital Management LP lifted its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) by 107.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,227 shares of the biotechnology company’s stock after purchasing an additional 3,228 shares during the quarter. Quantinno Capital Management LP’s holdings in Ligand Pharmaceuticals were worth $1,243,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of LGND. Legato Capital Management LLC increased its stake in Ligand Pharmaceuticals by 61.0% during the 4th quarter. Legato Capital Management LLC now owns 26,241 shares of the biotechnology company’s stock valued at $4,961,000 after buying an additional 9,944 shares during the period. UBS Group AG lifted its stake in shares of Ligand Pharmaceuticals by 27.8% in the 4th quarter. UBS Group AG now owns 143,067 shares of the biotechnology company’s stock worth $27,050,000 after acquiring an additional 31,081 shares during the period. Franklin Resources Inc. lifted its stake in shares of Ligand Pharmaceuticals by 115.9% in the 4th quarter. Franklin Resources Inc. now owns 496,160 shares of the biotechnology company’s stock worth $93,809,000 after acquiring an additional 266,304 shares during the period. Fisher Asset Management LLC boosted its holdings in shares of Ligand Pharmaceuticals by 20.1% in the fourth quarter. Fisher Asset Management LLC now owns 130,858 shares of the biotechnology company’s stock valued at $24,741,000 after acquiring an additional 21,932 shares in the last quarter. Finally, Future Fund LLC bought a new position in shares of Ligand Pharmaceuticals in the fourth quarter valued at approximately $1,755,000. Institutional investors and hedge funds own 91.28% of the company’s stock.

Insider Transactions at Ligand Pharmaceuticals

In other Ligand Pharmaceuticals news, Director Jason Aryeh sold 4,500 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $250.00, for a total value of $1,125,000.00. Following the transaction, the director owned 102,580 shares of the company’s stock, valued at approximately $25,645,000. This represents a 4.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jason Haas sold 7,138 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $292.81, for a total value of $2,090,077.78. Following the sale, the director owned 3,981 shares of the company’s stock, valued at $1,165,676.61. This trade represents a 64.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 71,976 shares of company stock valued at $20,075,721 in the last 90 days. 5.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research firms recently commented on LGND. Leerink Partners assumed coverage on shares of Ligand Pharmaceuticals in a research note on Friday. They set an “outperform” rating and a $330.00 price objective on the stock. Stifel Nicolaus upped their target price on Ligand Pharmaceuticals from $255.00 to $332.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. HC Wainwright increased their price target on Ligand Pharmaceuticals from $289.00 to $358.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Royal Bank Of Canada lifted their price target on Ligand Pharmaceuticals from $340.00 to $345.00 and gave the company an “outperform” rating in a research report on Friday, August 7th. Finally, Weiss Ratings raised Ligand Pharmaceuticals from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday. Nine equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Ligand Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $335.75.

Ligand Pharmaceuticals Stock Performance

NASDAQ:LGND opened at $294.60 on Friday. The company has a 50-day moving average of $291.80 and a 200-day moving average of $238.57. The firm has a market cap of $5.87 billion, a price-to-earnings ratio of 31.51, a price-to-earnings-growth ratio of 2.51 and a beta of 1.13. The company has a current ratio of 31.18, a quick ratio of 20.95 and a debt-to-equity ratio of 1.16. Ligand Pharmaceuticals Incorporated has a twelve month low of $149.51 and a twelve month high of $326.63.

Ligand Pharmaceuticals (NASDAQ:LGND) last released its earnings results on Thursday, August 6th. The biotechnology company reported $2.37 EPS for the quarter, topping analysts’ consensus estimates of $1.97 by $0.40. Ligand Pharmaceuticals had a net margin of 67.88% and a return on equity of 20.06%. The business had revenue of $63.69 million for the quarter, compared to the consensus estimate of $61.30 million. During the same period in the previous year, the firm earned $1.60 EPS. The business’s revenue for the quarter was up 33.8% on a year-over-year basis. Ligand Pharmaceuticals has set its FY 2026 guidance at 9.000-9.500 EPS. Analysts forecast that Ligand Pharmaceuticals Incorporated will post 4.89 earnings per share for the current fiscal year.

Ligand Pharmaceuticals Profile

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company’s product offerings center around several core platforms.